@article {Caetano2021.12.10.21267618, author = {Constantino Caetano and Maria Lu{\'\i}sa Morgado and Paula Patr{\'\i}cio and Andreia Leite and Ausenda Machado and Andr{\'e} Torres and Jo{\~a}o Freitas Pereira and S{\'o}nia Namorado and Ana Sottomayor and Andr{\'e} Peralta and Baltazar Nunes}, title = {Measuring the impact of COVID-19 vaccination and immunity waning: a modelling study for Portugal}, elocation-id = {2021.12.10.21267618}, year = {2021}, doi = {10.1101/2021.12.10.21267618}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Vaccination strategies to control COVID-19 have been ongoing worldwide since the end of 2020. Understanding their possible effect is key to prevent future disease spread. Using a modelling approach, this study intends to measure the impact of the COVID-19 Portuguese vaccination strategy on the effective reproduction number and explore three scenarios for vaccine effectiveness waning. Namely, the no-immunity-loss, 1-year and 3-years of immunity duration scenarios. We adapted an age-structured SEIR deterministic model and used Portuguese hospitalisation data for the model calibration. Results show that, although the Portuguese vaccination plan had a substantial impact in reducing overall transmission, it might not be sufficient to control disease spread. A significant vaccination coverage of those above 5 years old, a vaccine effectiveness against disease of at least 80\% and softer non-pharmaceutical interventions (NPIs), such as mask usage and social distancing, would be necessary to control disease spread in the worst scenario considered. The immunity duration scenario of 1-year displays a resurgence of COVID-19 hospitalisations by the end of 2021, the same is observed in 3-year scenario although with a lower magnitude. The no-immunity-loss scenario presents a low increase in hospitalisations. In both the 1-year and 3-year scenarios, a vaccination boost of those above 65 years old would result in a 53\% and 38\% peak reduction of non-ICU hospitalisations, respectively. These results suggest that NPIs should not be fully phased-out but instead be combined with a fast booster vaccination strategy to reduce healthcare burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge financial support from the Fundacao para a Ciencia e Tecnologia - FCT through project 692 2a edicao Research 4 covid, project name Projecao do Impacte das medidas Nao-farmacologicas de Controlo e mitigacao da epidemia de COVID-19 em Tempo ReaL (COVID-19 in-CTRL). The first author also acknowledges FCT within the PhD grants "DOCTORATES 4 COVID", number 2020.10172.BD. The second author also acknowledges FCT within projects UIDB/04621/2020 and UIDP/04621/2020. The third author also acknowledges FCT within the Strategic Project UIDB/00297/2020 (Centro de Matematica e Aplicacoes, Universidade Nova de Lisboa)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Committee (Comissao de Etica para a Saude) of the Portuguese National Institute of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2021/12/13/2021.12.10.21267618}, eprint = {https://www.medrxiv.org/content/early/2021/12/13/2021.12.10.21267618.full.pdf}, journal = {medRxiv} }